home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 06/01/20

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Granted SME Status by the European Medicines Agency

FLORHAM PARK, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has been granted Small ...
CLRB - Healthcare and Tech stocks among premarket losers

La Jolla Pharmaceutical (NASDAQ: LJPC ) -24% . More news on: La Jolla Pharmaceutical Company, Arcus Biosciences, Inc., Mitcham Industries, Inc., Stocks on the move, , Read more ...

CLRB - NVAX, LK among premarket ganers

Mmtec (NASDAQ: MTC ) +168%  on FY results . More news on: Mmtec, Inc., Sky Solar Holdings, Ltd., Cellectar Biosciences, Inc., Stocks on the move, , Read more ...

CLRB - Cellectar Bio's CLR 131 Fast Track'd for lymphatic system cancer

The FDA grants Fast Track status to Cellectar Biosciences (NASDAQ: CLRB ) CLR 131 application for patients with lymphoplasmacytic lymphoma (LPL)/ Waldenstrom’s macroglobulinemia (WM) in patients who have received at least two prior lines of therapy. More news on: Cellectar Biosci...
CLRB - Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration...

CLRB - Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

FLORHAM PARK, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Patent Office ...

CLRB - AMC, CYTK, MT and SALT among midday movers

Gainers: Cellect Biotechnology (NASDAQ: APOP ) +77% . More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., Remark Holdings, Inc., Stocks on the move, , Read more ...

CLRB - Expected capital raises continue to ramp in healthcare amid pandemic

The need for capital continues apace for healthcare companies as they deal with COVID-19 disruptions. More news on: Check-Cap Ltd., Cellectar Biosciences, Inc., BioTelemetry, Inc., Healthcare stocks news, , Read more ...

CLRB - Cellectar -13.3% on filing to offer shares

Cellectar Biosciences (NASDAQ: CLRB ) is 13.3% lower in light postmarket trading after filing to offer $17.5M worth of shares and prefunded warrants. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

CLRB - Cellectar Biosciences EPS misses by $0.07

Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.42 misses by $0.07 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Previous 10 Next 10